

Using Big Data to Identify Risk Factors for Opioid Abuse Among Patients with Opioid Prescriptions

BACKGROUND

According to CDC, there were nearly 72,000 Americans drug overdoses in 2019, a 5% increase from 2018. Death abuse continue to be high.

However, opioids are among the most important therapeutic medications for people with chronic diseases, chronic pain, or mental health disorders. Some studies showed that more than half of patients had an opioid prescription before their initial diagnosis of opioid overdose or opioid use disorders.

Therefore, it is critical to identify risk factors for opioid abuse among patients with opioid prescriptions, especially for patients who are prescribed opioids for the initial time.

SUBJECTS

The analytical dataset comprised information from IBM[®] MarketScan[®] database on privately insured individuals in the United States, from 2013 to 2017. The study estimated the opioid-related outcome models and identified risk factors for opioid abuse.

- Eligible population in the study: Patients who had opioid prescriptions.
- Opioid abuse outcomes:
 - -- Opioid overdose
 - -- Opioid use disorders
- Variables: \bullet
 - -- Patients' opioid prescription records:
- Morphine Milligram Equivalents (MME), opioid su -- Comorbidity, Mental health disorders, and Joint

procedures.

-- Demographic variables (e.g., age, gender, health plan enrollment history) were records at the initial opioid prescription obtained.

METHODS

The univariate analysis of each variable was applied to determine if differences in opioid abuse diagnoses were statistically significant. Any variable having a significant univariate test at 0.05 level is selected as a candidate for the multivariate analysis.

Multivariate logistic regression was used to estimate the association between the selected predictors (socio-demographics, comorbidity, mental health disorder, joint replacement procedures, etc.) and opioid abuse diagnoses.

Xingyue Huo, MS¹, Apoorva Pradhan, PhD², Fadia Shaya, PhD², Joseph Finkelstein, MD, PhD, FAMIA¹

¹Icahn School of Medicine at Mount Sinai, New York, NY, USA ²University of Maryland Schools of Pharmacy, Baltimore, MD, USA

RESULTS

Table 1. Demographic Description for Patients Disorder (2013-2017)

wh	no die	d	from
hs	from	d	rug

upply	days
replac	cement

	Opioid Use Disorder		Over	Overdose	
	Yes	No	Yes	No	
Region					
Northeast Region	68	222,012	13	222,067	
North Central Region	131	322,816	17	322,930	
South Region	146	522,856	26	522,976	
West Region	245	388,671	20	388,896	
Unknown Region	11	36,624	0	36,635	
Health Plan					
Commercial	506	1,304,252	59	1,304,699	
Medicare	95	188,727	17	188,805	
Sex					
Male	278	577,263	26	577,515	
Female	323	915,716	50	915,989	
Age Groups			_		
0-17 years	6	150,984	5	150,985	
18–24 years	40	106,498	11	106,527	
25–34 years	61	1/8,32/	14	1/8,3/4	
35–44 years	80	247,203	/	247,276	
45-54 years	143	290,534	8 16	290,009	
55-04 years	103	202 438	10	202 526	
Mornhine Milliaram Equivalents (MME)	103	202,438	13	202,520	
0-20	9559	480 052	356	489 255	
21-50	19780	682,894	722	701.952	
51-90	12653	152.411	382	164.682	
91+	3528	74,867	167	78,228	
Joint Replacement		,		,	
No	43278	1,350,313	1523	1,392,068	
Yes	2242	39,911	104	42,049	
Comorbidity Flag					
No	25820	1,000,721	647	1,025,894	
Yes	18243	346,661	927	363,977	
Mental Disorder					
No	26883	1,164,197	652	1,190,428	
Yes	17180	183,185	922	199,443	
Number of days supply for opioids					
0-3 days	5337	443,445	275	448,507	
4-7 days	8080	480,513	340	488,253	
8-15 days	7314	240,816	342	247,788	
16-30 days	24013	206,074	643	229,444	
31-60 days	324	6,181	7	6,498	
61-90 days	448	12,982	20	13,410	
90+ days	4	213	•	217	
Ago at Indox Dato (Maga)	ГО		<i>л</i> г	<i>л</i> г	
Age at maex Date (IVIean) Number of days supply for origida (March)	5U 25 2	45	45	45 1 4 5	
warnber of days supply for opioids (iviedn)	25.2	14.3	20.3	14.3	

Table 2. Summary Statistics for Univariate Regression Analysis (Dep

Variab	les	Odds Ratio	95% (P-Value
Health Plan	Commercial vs Medicare	1.45	1.34	1.56	<.0001
Age Group	18–24 years vs 0-17 years	5.64	5.23	6.08	<.0001
	25–34 years vs 0-17 years	5.94	5.52	6.38	<.0001
	35–44 years vs 0-17 years	6.61	6.15	7.09	<.0001
	45–54 years vs 0-17 years	6.50	6.05	6.97	<.0001
	55–64 years vs 0-17 years	5.28	4.92	5.67	<.0001
	65+ years vs 0-17 years	3.13	2.83	3.46	<.0001
Sex	Female vs Male	0.82	0.81	0.83	<.0001
Geographical Region	Northeast vs South	0.62	0.60	0.63	<.0001
	North Central vs South	0.71	0.69	0.72	<.0001
	West vs South	0.53	0.51	0.54	<.0001
	Unknown vs South	0.99	0.93	1.05	0.6557
Had Joint Replacement	Yes vs No	1.64	1.26	1.40	<.0001
At Least One Comorbidity	Yes vs No	1.72	0.92	1.11	0.7794
At Least One Mental Disorder	Yes vs No	4.12	0.85	0.93	<.0001
Opioids Medicine Supply Days	4-7 days vs0-3 days	1.46	1.43	1.50	<.0001
	8-15 days vs0-3 days	2.03	1.98	2.09	<.0001
	16-30 days vs 0-3 days	4.52	4.40	4.65	<.0001
	31-60 days vs 0-3 days	7.46	7.23	7.69	<.0001
	61-90 days vs 0-3 days	3.95	3.20	4.87	<.0001
MME Group	0-20 vs 21-50	0.44	1.69	1.75	<.0001
	51-90 vs 21-50	1.72	4.05	4.18	<.0001
	91+ vs 21-50	1.09	4.40	4.65	<.0001

with	Overdose	r/ Opioid	' Use

endent variable= Opioid Use Disord	le)

Age Group	
Nge Group	
ex	
Geographical Region	
lad Loint Ponlacomont	
ida Joint Replacement	
At Least One Comorbidity	у
At Least One Mental Diso	order

- respectively (Table 1).
- significantly decreased, in general.
- as age increased (p<.001).
- opioids than patients who did not.
- diagnoses, respectively.

CONCLUSIONS

This study analyzed risk factors for opioid overdose/opioid use disorder in patients with opioid prescriptions. The opioid medication prescription should take into account individuals at high risk for opioid overdose/opioid use disorder.

RESULTS

riate Regression Analysis (Dependent variable= Overdose)

	Odds Ratio	95%	S CI	P-Value		
Commercial vs Medicare	0.64	0.48	0.86	0.0027		
8–24 years vs 0-17 years	3.76	3.04	4.64	<.0001		
5–34 years vs 0-17 years	1.73	1.39	2.15	<.0001		
5–44 years vs 0-17 years	1.17	0.94	1.46	0.1523		
5–54 years vs 0-17 years	1.25	1.01	1.55	0.0373		
5–64 years vs 0-17 years	1.00	0.81	1.24	0.9936		
65+years vs 0-17 years	0.66	0.47	0.94	0.0212		
Female vs Male	0.87	0.81	0.94	0.0002		
Northeast vs South	1.15	1.04	1.28	0.0096		
North Central vs South	1.11	1.01	1.22	0.038		
West vs South	0.98	0.88	1.09	0.6954		
Unknown vs South	1.20	0.85	1.68	0.2955		
Yes vs No	2.32	2.00	2.70	<.0001		
Yes vs No	2.68	2.48	2.90	<.0001		
Yes vs No	7.22	6.70	7.78	<.0001		
4-7 days vs 0-3 days	1.22	1.09	1.36	0.0007		
8-15 days vs 0-3 days	1.68	1.49	1.89	<.0001		
16-30 days vs 0-3 days	2.69	2.36	3.07	<.0001		
31-60 days vs 0-3 days	2.83	2.40	3.33	<.0001		
61-90 days vs 0-3 days	1.30	0.42	4.06	0.6517		
0-20 vs 21-50	0.50	0.46	0.55	<.0001		
51-90 vs 21-50	1.60	1.41	1.82	<.0001		
91+ vs 21-50	1.53	1.30	1.81	<.0001		

• Between 2013 and 2017, a total of 4,793,793 individuals received opioid prescriptions, of which 3,092 (0.06%) and 72,910 (1.52%) patients were diagnosed with opioid overdose and OUD after initial prescriptions

• In Table 2-3, as the average MME for the opioid drug in prescription increased, the proportion diagnosed with opioid overdose/ OUD

• After adjusting for covariates, multiple logistic regressions showed that people aged 18-24 years were 3.8 times (95% CI:3.1-4.7) more likely to have opioid overdose than those under 18 years old, while 18-24 years were 5.6 times (95% CI:5.2-6.1) more likely to be OUD than those under 18 years old. Significantly, there was a tendency for this rate to decrease

• Women were about 10% less likely to opioid overdose/ OUD than men. • Also, patients were significantly 2.3 times more likely to overdose

• Patients who had at least one comorbidity or at least one mental illness or patients who had joint replacement procedures were significantly more likely to overdose opioids/OUD than patients without these